TrialESMO open2026

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

D M Filippini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.